RS63243B1 - Lečenje parkinsonove bolesti - Google Patents

Lečenje parkinsonove bolesti

Info

Publication number
RS63243B1
RS63243B1 RS20220497A RSP20220497A RS63243B1 RS 63243 B1 RS63243 B1 RS 63243B1 RS 20220497 A RS20220497 A RS 20220497A RS P20220497 A RSP20220497 A RS P20220497A RS 63243 B1 RS63243 B1 RS 63243B1
Authority
RS
Serbia
Prior art keywords
formula
compound
compounds
acid
abl
Prior art date
Application number
RS20220497A
Other languages
English (en)
Serbian (sr)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji Mandhane
Manoj Atmaramji Upadhya
Sameer Vishwanath Mehetre
Gajanan Uttamrao Chidrewar
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of RS63243B1 publication Critical patent/RS63243B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20220497A 2016-06-02 2017-06-02 Lečenje parkinsonove bolesti RS63243B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019087 2016-06-02
IN201621019185 2016-06-02
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
RS63243B1 true RS63243B1 (sr) 2022-06-30

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220497A RS63243B1 (sr) 2016-06-02 2017-06-02 Lečenje parkinsonove bolesti

Country Status (27)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP3463351B1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CA (1) CA3024976A1 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
KR102508288B1 (ko) 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMAL STORAGE DISORDERS
KR20220024463A (ko) * 2019-06-11 2022-03-03 썬 파마 어드밴스트 리서치 컴패니 리미티드 시뉴클레인병증에 대한 치료
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
AU2021317186A1 (en) 2020-07-31 2023-03-16 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of Alzheimer's Disease
US20250275953A1 (en) 2022-05-02 2025-09-04 Sun Pharma Advanced Research Company Ltd. Vodobatinib for reducing progression of parkinson's disease
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012208388C1 (en) * 2011-01-21 2017-04-27 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
CA2911040C (en) 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
MX2017014752A (es) * 2015-05-18 2018-03-23 Sun Pharma Advanced Res Co Ltd Nuevos etinos de amidoheteroaril aroil hidrazida.
KR102508288B1 (ko) * 2016-06-02 2023-03-09 썬 파마 어드밴스트 리서치 컴패니 리미티드 파킨슨병의 치료

Also Published As

Publication number Publication date
DK3463351T3 (da) 2022-06-07
US20240066014A1 (en) 2024-02-29
MX2018014944A (es) 2019-03-07
CN109475539A (zh) 2019-03-15
PL3463351T3 (pl) 2022-06-20
WO2017208267A1 (en) 2017-12-07
US20210015805A1 (en) 2021-01-21
EP3463351B1 (en) 2022-04-27
SI3463351T1 (sl) 2022-07-29
BR112018074439A2 (pt) 2019-03-06
NZ748592A (en) 2025-11-28
UA123018C2 (uk) 2021-02-03
CL2018003431A1 (es) 2019-05-10
AU2017273415A1 (en) 2018-12-06
PT3463351T (pt) 2022-06-02
US20190275017A1 (en) 2019-09-12
LT3463351T (lt) 2022-06-10
US20220273632A1 (en) 2022-09-01
HUE059387T2 (hu) 2022-11-28
ES2914782T3 (es) 2022-06-16
SMT202200228T1 (it) 2022-07-21
MX385276B (es) 2025-03-18
PH12018502457B1 (en) 2022-01-12
EP4085912A1 (en) 2022-11-09
US10849887B2 (en) 2020-12-01
PH12018502457A1 (en) 2019-10-21
IL263188B (en) 2021-08-31
EP3463351A1 (en) 2019-04-10
KR20190015257A (ko) 2019-02-13
IL263188A (en) 2018-12-31
SG11201810294QA (en) 2018-12-28
CN109475539B (zh) 2021-12-28
US11583522B2 (en) 2023-02-21
US11813252B2 (en) 2023-11-14
CA3024976A1 (en) 2017-12-07
MY193754A (en) 2022-10-27
HRP20220683T1 (hr) 2022-07-08
CY1125285T1 (el) 2025-03-28
JP2019520344A (ja) 2019-07-18
AU2017273415B2 (en) 2023-01-19
KR102508288B1 (ko) 2023-03-09
JP6974357B2 (ja) 2021-12-01

Similar Documents

Publication Publication Date Title
RS63243B1 (sr) Lečenje parkinsonove bolesti
AU2009277086B2 (en) Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
JP6509386B2 (ja) mTOR経路関連疾患を治療するための化合物
CA2501932A1 (en) Use of benzimidazole quinolinones for treating cancer
KR20130073873A (ko) 간암의 치료에 사용하기 위한 유기 화합물
JP2005516948A (ja) 新規な使用
US20220362251A1 (en) Treatment of tachycardia
HK40082665A (en) Treatment for parkinson s disease
WO2017165812A1 (en) Apkc inhibitors and methods of treating a neurodegenerative disease or disorder
RU2258506C2 (ru) Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний
OA19279A (en) Treatment for Parkinson's disease.
EA037697B1 (ru) Лечение болезни паркинсона
BR122024006410A2 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson
BR112018074439B1 (pt) Uso do composto de fórmula i para o tratamento ou prevenção da doença de parkinson
US11116741B2 (en) Method for the treatment of valvular heart disease comprising administering a composition comprising sarpogrelate
JP2008056565A (ja) 遅発性神経細胞死を防御または救済するための薬剤および方法